Search

Background/Aims The recently proposed metabolic dysfunction-associated steatotic liver disease (MASLD) has been put forth as a more accurate representation of the metabolic aspects of fatty liver disease. The objective of this study was to examine the relationship between the various subtypes of SLD and the subsequent development of atrial fibrillation. Methods We identified participants who underwent health screenings in 2009 and 2010 using the KNHIS database and conducted a retrospective analysis of their data through 2019. The subjects were classified into six categories: no SLD without risk factor, no SLD with risk factor, MASLD without alcohol, MASLD with alcohol, MASLD with increased alcohol intake (MetALD), and alcohol-related liver disease (ALD). Hepatic steatosis was defined as fatty liver index ≥30. The primary outcome was the occurrence of newly diagnosed atrial fibrillation and ischemic stroke. Results There were 107,202 male (51.0%) and 102,751 female (49.0%). The adjusted hazard ratio (aHR) of the incidence of atrial fibrillation was derived as no SLD with risk factor 1.41 [95% CI: 1.24-1.60], MASLD with no alcohol 1.80 [95% CI: 1.57-2.06], MASLD with alcohol 1.93 [95% CI: 1.67-2.22], MetALD 2.21 [95% CI: 1.85-2.63], and ALD 1.88 [95% CI: 1.45-2.43] using No SLD without risk factor as a reference. The aHR of the incidence of Ischemic stroke was derived as no SLD with risk factor 1.59 [95% CI: 1.38-1.83], MASLD with no alcohol 2.04 [95% CI: 1.76-2.36], MASLD with alcohol 1.89 [95% CI: 1.62-2.21], MetALD 2.31 [95% CI: 1.91-2.79], and ALD 2.31 [95% CI: 1.78-2.98] using No SLD without risk factor as a reference. Conclusion We observed an increased prevalence of atrial fibrillation and ischemic stroke, a complication of atrial fibrillation, associated with the presence of cardiometabolic risk factors the presence of SLDs, and increased alcohol intake. [ABSTRACT FROM AUTHOR]

Background/Aims A recent Delphi consensus proposed a new classification system for steatotic liver disease (SLD), replacing the previous terminology, non-alcoholic fatty liver disease (NAFLD). This study aimed to examine the association between SLD subtypes and the risk of developing colorectal cancer (CRC). Methods We used the Korean National Health Insurance Service database to identify participants who underwent health screenings in 2009 and 2010 and retrospectively analysed their data through to 2019. The participants were grouped into four categories: no SLD, metabolic dysfunction-associated steatotic liver disease (MASLD), MASLD with increased alcohol intake (MetALD), and alcohol-related liver disease (ALD). Hepatic steatosis was defined as a fatty liver index ≥30. The primary outcome was the occurrence of newly diagnosed CRC according to the SLD classification. Results This analysis included 242,275 participants. The adjusted hazard ratios for CRC incidence were 1.17 (95% confidence interval [CI]: 1.10–1.25) for MASLD, 1.45 (95% CI: 1.28 –1.65) for MetALD, and 1.78 (95% CI: 1.48–2.14) for ALD, with no SLD as the reference group. All results were statistically significant (p<0.001). Conclusion: Individuals in Korea with MASLD, MetALD, or ALD are at an increased risk of developing CRC [ABSTRACT FROM AUTHOR]

Background/Aims In June 2023, an international panel of experts put forth a proposal to introduce a new classification system for steatotic liver disease (SLD), which would replace the previous terminology of nonalcoholic fatty liver disease (NAFLD). The objective of this study was to examine the relationship between the various subtypes of SLD and the subsequent development of esophageal and gastric cancers. Methods We identified participants who underwent health screenings in 2009 and 2010 using the KNHIS database and conducted a retrospective analysis of their data through 2019. The subjects were classified into four categories: no SLD, metabolic dysfunction-associated steatotic liver disease (MASLD), MASLD with increased alcohol intake (MetALD), and alcohol- related liver disease (ALD). Hepatic steatosis was defined as fatty liver index ≥30. The primary outcome was the occurrence of newly diagnosed esophageal and gastric cancers. Results There were 109,698 male (50.8%) and 105,868 female (49.2%). The prevalence of no SLD, MASLD, MetALD, and ALD was 63.3%, 31.9%, 3.7%, and 1.0%, respectively. The adjusted hazard ratio (aHR) of the incidence of esophageal cancer was derived as MASLD 0.81 [95% CI: 0.61-1.08], MetALD 1.58 [95% CI: 1.00-2.51], and ALD 2.23 [95% CI: 1.20-4.14] using No SLD as a reference. The aHR of the incidence of stomach cancer was derived as MASLD 1.08 [95% CI: 1.01-1.60], MetALD 1.38 [95% CI: 1.19-1.60], and ALD 1.39 [95% CI: 1.09-1.76] using No SLD as a reference. Conclusion There is a notable correlation between esophageal cancer and ALD. Individuals with MASLD, MetALD, and ALD are at an elevated risk of developing gastric cancer. [ABSTRACT FROM AUTHOR]